GALE News 2.29 04/24/2014 05:24:00 Galena Biopharma (GALE)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Galena Biopharma (GALE) 2.29 $GALE

GALENA BIOPHARMA, INC. SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of Class Action Against GALENA BIOPHARMA, INC. and Its Board and a Lead Plaintiff Deadline of May 5, 2014 -- GALE
GlobeNewswire - Wed Apr 23, 6:16PM CDT
Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the District of Oregon on behalf of holders of Galena Biopharma, Inc. ("Galena" or the "Company" (Nasdaq:GALE) securities between November 6, 2013 and February 14, 2014.

Top Gainers at a Glance -- Research on Trina Solar, Yingli Green Energy Holding, Galena Biopharma, and Conn's
PR Newswire - Wed Apr 23, 10:43AM CDT
The US markets saw a positive sentiment on Tuesday, April 22, 2014, with the NASDAQ Composite closing at 4,161.46, up 0.97%, the Dow Jones Industrial Average ending the session at 16,514.37, up 0.40%, and the S&P 500 gained 0.41%, to finish the trading session at 1,879.55. The gains were broad based as eight out of ten sectors ended the session in positive. A number of stocks saw large movements, including Trina Solar Ltd (NYSE: TSL), Yingli Green Energy Holding Co. Ltd (NYSE: YGE), Galena Biopharma Inc. (NASDAQ: GALE) and Conn's Inc. (NASDAQ: CONN). Free technical research on TSL, YGE, GALE and CONN can be downloaded upon signing up at:

EQUITY ALERT: Rosen Law Firm Reminds Galena Biopharma, Inc. Investors of Important May 5, 2014 Class Action Deadline -- GALE
GlobeNewswire - Tue Apr 22, 4:07PM CDT
The Rosen Law Firm, P.A. today reminds all purchasers of the common stock of Galena Biopharma, Inc. (Nasdaq:GALE) between November 6, 2013 and February 14, 2014, inclusive of the important May 5, 2014 lead plaintiff deadline in the class action filed by the firm.

INVESTOR ALERT: Law Offices of Howard G. Smith Announces an Expanded Class Period in the Shareholder Lawsuit against Galena Biopharma, Inc.
Business Wire - Tue Apr 22, 9:32AM CDT
Law Offices of Howard G. Smith announces that the class action lawsuit against Galena Biopharma, Inc. ("Galena" or the "Company" (NASDAQ:GALE) filed in the United States District Court for the District of Oregon has been expanded to include all purchasers of Galena common stock between May 9, 2013 and March 17, 2014, inclusive (the "Class Period" .

SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses in Excess of $100,000 from Investment in Galena Biopharma, Inc. to Contact Brower Piven Before the May 5, 2014 Lead Plaintiff Deadline (GALE)
GlobeNewswire - Mon Apr 21, 5:20PM CDT
Brower Piven, A Professional Corporation announces that a class action lawsuit has been commenced in the United States District Court for the District of Oregon on behalf of purchasers of Galena Biopharma, Inc. ("Galena" or the "Company" (Nasdaq:GALE) common stock during the period between November 6, 2013 and February 14, 2014, inclusive (the "Class Period" .

U.S. District Court Judge Nixes Banning of Zogenix's Painkiller in Massachusetts
ACCESSWIRE - Mon Apr 21, 9:42AM CDT
A U.S. District Court judge stopped Massachusetts from banning the sale of Zogenix Inc.'s (NASDAQ: ZGNX) prescription painkiller Zohydro, saying that the decision was based on the principle that federal law superseded the state's action.

Hagens Berman: Galena Biopharma Investigation Proceeds in Light of May 5, 2014 Lead Plaintiff Deadline in Securities Fraud Class Actions
PR Newswire - Wed Apr 16, 6:56PM CDT
Hagens Berman Sobol Shapiro LLP an investor-rights law firm with offices in San Francisco has intensified its investigation on behalf of Galena Biopharma, Inc. (NASDAQ: GALE) ("Galena" or "the Company" in light of the May 5, 2014 deadline to file for lead plaintiff in the securities fraud cases against the company. Investors who purchased Galena stock between May 9, 2013 and March 17, 2014 (the "Class Period" can contact Hagens Berman Partner Reed Kathrein, who is leading the firm's investigation, by calling 510-725-3000, emailing Galena@hbsslaw.com or visiting http://hb-securities.com/investigations/Galena.

Valuation Doesn't Equal Share Price (and That Goes Double for Biotech)
Brian Orelli, The Motley Fool - Motley Fool - Mon Apr 14, 6:52PM CDT
Most investors realize that share price is meaningless when comparing companies. A company at $50 per share might actually be worth more than a company at $100 per share because a company's value is determined by the number of outstanding shares in...

Lieff Cabraser Reminds Galena Biopharma, Inc. Investors of Upcoming Deadline in Class Action Litigation - GALE
Business Wire - Fri Apr 11, 5:28PM CDT
Lieff Cabraser Heimann & Bernstein, LLP reminds investors of the May 5, 2014 deadline to move for appointment as lead plaintiff in the securities class litigation brought on behalf of those who purchased or otherwise acquired the securities of Galena Biopharma, Inc. ("Galena" or the "Company" (Nasdaq:GALE) between May 9, 2013 and March 17, 2014, inclusive (the "Class Period" .

SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Galena Biopharma, Inc. and Certain Officers - GALE
PR Newswire - Fri Apr 11, 3:14PM CDT
Pomerantz LLP has filed a class action lawsuit against Galena Biopharma, Inc. ("Galena" or the "Company" (NASDAQ: GALE) and certain of its officers. The class action, filed in United States District Court, District of Oregon, and docketed under 3:14-cv-00410-HZ, is on behalf of a class consisting of all persons or entities who purchased or otherwise acquired Galena securities between March 12, 2013 and February 11, 2014, both dates inclusive (the "Class Period" . This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws pursuant to Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder.

SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses in Excess of $100,000 from Investment in Galena Biopharma, Inc. to Contact Brower Piven Before the May 5, 2014 Lead Plaintiff Deadline
Business Wire - Wed Apr 09, 4:14PM CDT
Brower Piven, A Professional Corporation announces that a class action lawsuit has been commenced in the United States District Court for the District of Oregon on behalf of purchasers of Galena Biopharma, Inc. ("Galena" or the "Company" (Nasdaq: GALE) common stock during the period between November 6, 2013 and February 14, 2014, inclusive (the "Class Period" .

Financial Results Schedules, Approvals, Appointments, Product Launches, and Stock Movements - Analyst Notes on Allergan, Accuray, Cerus, Galena Biopharma, and ZELTIQ Aesthetic
PR Newswire - Wed Apr 09, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Allergan Inc. (NYSE: AGN), Accuray Incorporated (NASDAQ: ARAY), Cerus Corporation (NASDAQ: CERS), Galena Biopharma, Inc. (NASDAQ: GALE), and ZELTIQ Aesthetics, Inc. (NASDAQ: ZLTQ). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register

Hagens Berman Notifies Investors of Extended Class Period and May 5, 2014 Lead Plaintiff Deadline in Galena Biopharma, Inc. Securities Fraud Class Actions
PR Newswire - Mon Apr 07, 4:23PM CDT
Hagens Berman Sobol Shapiro LLP reminds investors of the May 5, 2014 deadline to file for lead plaintiff in a securities fraud case against Galena Biopharma, Inc. (NASDAQ: GALE) ("Galena" or "the Company" . The Class Period has been extended to cover investors who bought stock between May 9, 2013 and March 17, 2014 (the "Class Period" . Investors who purchased Galena securities during the Class Period may contact Hagens Berman Partner Reed Kathrein, who is leading the firm's investigation, by calling 510-725-3000, emailing Galena@hbsslaw.com or visiting http://hb-securities.com/investigations/Galena.

INVESTOR ALERT: Glancy Binkow & Goldberg LLP Reminds Investors of the Lead Plaintiff Deadline in the Class Action Lawsuit Against Galena Biopharma, Inc.
Business Wire - Thu Apr 03, 12:03PM CDT
Glancy Binkow & Goldberg LLP reminds investors of Galena Biopharma, Inc. ("Galena" or the "Company" (NASDAQ:GALE) that all purchasers of Galena securities between November 6, 2013 and February 14, 2014, inclusive (the "Class Period" , have until May 5, 2014, to file a motion to be appointed as lead plaintiff in the shareholder lawsuit.

Galena Biopharma to Present at the 13th Annual Needham Healthcare Conference
GlobeNewswire - Thu Apr 03, 6:05AM CDT
Galena Biopharma (Nasdaq:GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology treatments that address major unmet medical needs to advance cancer care, today announced that Mark J. Ahn, Ph.D., President and Chief Executive Officer will present a corporate update at the 13th Annual Needham Healthcare Conference. The presentation will take place on Tuesday, April 8, 2014 at 8:40 a.m. ET at the Westin Grand Central Hotel in New York, NY.

FDA Panel Grants Market Approval of MannKind Corp.'s Inhalable Insulin
ACCESSWIRE - Wed Apr 02, 8:49AM CDT
On Apr. 1, MannKind Corp. (NASDAQ:MNKD) announced that the Endocrinologic and Metabolic Drugs Advisory Committee of the FDA voted 13 to 1 to recommend that Afrezza, its inhalable insulin, be granted marketing approval by the FDA to improve glycemic control in adults with type 1 diabetes.

Morning Analysis on Top Gainers -- Research on Teva Pharmaceutical Industries, Capstone Turbine, Cigna, and Galena Biopharma
PR Newswire - Tue Apr 01, 8:29AM CDT
The US markets saw a positive sentiment on Monday, March 31, 2014, with the NASDAQ Composite closing at 4,198.99, up 1.04%, the Dow Jones Industrial Average ending the session at 16,457.66, up 0.82% and the S&P 500 edging 0.79% higher to finish the trading session at 1,872.34. The gains were broad based as nine out of 10 sectors ended the session in positive. A number of stocks saw large movements, including Teva Pharmaceutical Industries Ltd (NYSE: TEVA), Capstone Turbine Corp. (NASDAQ: CPST), Cigna Corp. (NYSE: CI) and Galena Biopharma Inc. (NASDAQ: GALE). Free technical research on TEVA, CPST, CI and GALE can be downloaded upon signing up at:

Hagens Berman Reminds Galena Biopharma, Inc. Investors of May 5, 2014, Lead Plaintiff Deadline and Continued Securities Fraud Investigation
Business Wire - Mon Mar 31, 12:37PM CDT
Hagens Berman Sobol Shapiro LLP reminds investors of the May 5, 2014, deadline to file for lead plaintiff in a securities fraud case against Galena Biopharma, Inc. (NASDAQ: GALE) ("Galena" or "the Company" . Investors who bought Galena securities between Nov. 6, 2013, and Feb. 14, 2014 (the "Class Period" , can contact Hagens Berman Partner Reed Kathrein, who is leading the firm's investigation, by calling 510-725-3000, emailing Galena@hbsslaw.com or by visiting http://hb-securities.com/investigations/Galena.

Today's Dead Cat Bounce Stock: Galena Biopharma (GALE)
at The Street - Mon Mar 31, 8:49AM CDT
Trade-Ideas LLC identified Galena Biopharma (GALE) as a "dead cat bounce" (down big yesterday but up big today) candidate
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Polsen Flex Deal Puts Pre-Tax Funds Behind Wearables

Updated Category News Views 141

A pile of soon-to-expire FSA cash is a peculiar sales catalyst, but Polsen Health has found one. The Amsterdam-based preventative-health wearable company is partnering with Flex to let customers pay for every Polsen watch and strap using eligible HSA or FSA funds at checkout. No reimbursement chase, no claim forms, and buyers can split the cost with another card. For a...

Continue Reading
Luxor Targets Device Chaos With Kwik IQ Hub Lockers

Updated Category News Views 86

A dead scanner at shift change can make an expensive digital rollout look downright foolish. Luxor Workspaces is aiming squarely at that unglamorous mess with its newly available Kwik IQ Hub smart-locker collection, introduced at the Connected Worker: Manufacturing Summit in Chicago on October 13–15. The pitch is not flashy: put shared radios, scanners, headsets,...

Continue Reading
Abbe Lane Estate Puts Jewelry Demand on Full Display

Updated Category News Views 0

Glamour Is Walking Back Into the Auction Room Abbe Lane’s jewelry is not being offered as a vague nostalgia exercise; it is arriving with dates, a setting, and a clear split between two December sales. John Moran Auctioneers will lead with The Estate of Abbe Lane on Wednesday, December 9, 2026, at 10:00 a.m. PST, then follow with its Jewelry & Watches auction on...

Continue Reading
Italian Wine Faces U.S. Slump and New Market Openings

Updated Category News Views 154

American demand has put a cork in the easy story, and Italian wine producers cannot pretend otherwise. In the first nine months of 2026, U.S. imports of Italian wine dropped 18.4% by value. That is painful because the United States remains Italy's largest destination market by value, not some side shelf that can be ignored until conditions improve. Still, the broader U.S....

Continue Reading
Fidelis Puts $140,000 Behind Statewide Postpartum Care

Updated Category News Views 114

A missed postpartum appointment can look like a small administrative failure until it is not. Fidelis Care’s $140,000 round of Here for Your Health maternal health grants is aimed squarely at that unglamorous but consequential gap: keeping new mothers connected to care after delivery, particularly in underserved New York communities. Small Dollars, Very Specific...

Continue Reading
Kuaishou’s AI Push Meets a Brutal Earnings Reality

Updated Category News Views 24

Kuaishou just put a very expensive wrinkle in its AI story. The third-quarter figures are not a minor wobble: revenue dropped 11.1% year over year to RMB31.6 billion, gross margin slid from 54.7% to 48.2%, and the company swung from a RMB4.5 billion profit to a RMB959 million loss. For holders of 01024, that is the sort of earnings release that demands less daydreaming...

Continue Reading
Radiology Staffing Gap Deepens as Imaging Demand Rises

Updated Category News Views 112

An imaging order does not mean much if nobody is available to read it, and that plain operational fact sits at the center of Medicus Healthcare Solutions' 2026 report on the radiologist shortage. The report's projected gap of 2,450 full-time-equivalent radiologists in 2027 is troubling enough. Its estimate of a 4,130 FTE shortfall by 2032 is the part that should make...

Continue Reading
Vizsla's Panuco Delay Puts Security Ahead of Speed

Updated Category News Views 0

A mine schedule can absorb a calendar slip; the people around a mine cannot be treated like a line item. Vizsla Silver's update on Panuco is therefore not the usual development-company chest thumping. It is a sober admission that security, permitting and site readiness have pushed first silver to the second half of 2028, one year later than the prior H2 2027 target....

Continue Reading
Ajman Media Forum Puts Trust Ahead of AI Speed in 2026

Updated Category News Views 6

Algorithms may manufacture a flood of words, but they cannot inherit accountability. That was the sensible nerve running through Ajman Media Forum 2026, “The Signal,” inaugurated on November 19 by His Highness Sheikh Ammar bin Humaid Al Nuaimi, Crown Prince of Ajman and Chairman of the Executive Council. For all the fanfare that usually surrounds artificial...

Continue Reading
Rare Stellar Merger Validates RIT Theory in Nature

Updated Category News Views 62

One star swallowed another’s orbit, and astronomy finally caught the evidence. That is the plain-English punch of the observation called AT 2025abao in the Andromeda Galaxy, and it is a meaningful one for Jason Nordhaus and his colleagues at Rochester Institute of Technology. On Nov. 18, research published in Nature validated a scenario Nordhaus’s team had predicted...

Continue Reading

Top 5 Most Recently Viewed Articles

Avanos Medical's Upcoming Earnings: Insights and Risks Ahead

Updated Category News Views 187

Riding the Earnings Wave with Avanos Medical Here we are again, staring down the barrel of another earnings report from Avanos Medical (NYSE:AVNS). It’s set to hit the airwaves on February 24, 2026. Now, I can’t help but think back to previous quarterly reports and the rollercoaster ride those brought. Sometimes it feels like a game of bingo—everyone’s hoping for...

Continue Reading
Agibank's Impressive Financial Growth and Market Strategies

Updated Category News Views 304

Agibank Reports Remarkable Financial Performance Agibank, the innovative digital bank, has showcased strong financial performance, marking substantial growth in its metrics. The bank has effectively combined the efficiency of digital banking with the valuable presence of physical locations, allowing it to flourish in a competitive market. Net Income and Loan Portfolio...

Continue Reading
AllianceBernstein Reports Strong Earnings Growth for AWF

Updated Category News Views 121

AllianceBernstein Global High Income Fund, Inc. Earnings Overview AllianceBernstein Global High Income Fund, Inc. (AWF), a prominent player in the closed-end investment company sector, recently shared its earnings for the first quarter ending June 30. This report highlights the fund's performance, showcasing its growth and resilience amid changing market conditions. Net...

Continue Reading
Experience the Enchantment of Yoobi's Wicked Collection Launch

Updated Category News Views 226

Introducing Yoobi's Wicked Collaboration Unleash your creativity with an enchanting stationery collection inspired by the Wizard of Oz. A Magical New Collection Yoobi, a mission-driven stationery brand, has recently unveiled its latest collaboration with a theme that captures the essence of friendship and individuality inspired by the beloved characters Glinda and Elphaba...

Continue Reading
Deadline Confirmed for NB Bancorp and Provident Merger Process

Updated Category News Views 274

Merger Details Between NB Bancorp and Provident Bancorp NB Bancorp, Inc. (Nasdaq: NBBK), the parent company of Needham Bank, and Provident Bancorp, Inc. (Nasdaq: PVBC), the holding company for BankProv, have announced important details related to their upcoming merger. This strategic merger aims to strengthen both institutions and create greater value for shareholders....

Continue Reading